

# GAVI Alliance Demand-side Innovation Policies

*Presentation at the Multi-year Expert Meeting on Investment, Innovation and Entrepreneurship for Productive Capacity-building and Sustainable Development*

*Lauren Franzel, Senior Specialist, Market Shaping*

*21 March 2014 – Palais des Nations*



# Mission and strategic goals 2011–2015

*To save children's lives and protect people's health by increasing access to immunisation in poor countries*

---

**1 The vaccine goal**  
Accelerate the uptake and use of underused and new vaccines

**2 The health systems goal**  
Contribute to strengthening the capacity of integrated health systems to deliver immunisation


---

**3 The financing goal**  
Increase the predictability of global financing and improve the sustainability of national financing for immunisation


---

**4 The market shaping goal**  
Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices

# The GAVI Alliance: an innovative partnership based on mutual accountability




**GAVI countries  
birth cohort**



**Non-GAVI countries  
birth cohort**

2012  
global birth cohort:  
**135 million**

**GAVI countries birth cohort:  
80 million**



Delivered together  
GAVI Alliance 2000–2013

440,000,000


additional children immunised

6,000,000

future deaths averted



# Countries co-finance vaccines based on what they can afford



# Overview of GAVI vaccination programmes

Measles rubella

HPV

Meningitis A

Pneumococcal

Rotavirus

Measles

Pentavalent


Hib

Yellow fever

Hepatitis B



# Why vaccines against pneumococcal disease?






# Introduction to the pneumococcal AMC - Objectives

The overarching goal of the pneumococcal Advanced Market Commitment (AMC) is to reduce morbidity and mortality from pneumococcal diseases. The pneumococcal AMC is designed to:

- **accelerate the development** of vaccines that meet developing country needs
- **bring forward the availability** of effective pneumococcal vaccines - through scaling up of production capacity to meet developing country vaccine demand
- **accelerate vaccine uptake** - through predictable vaccine pricing for countries and manufacturers
- **test the concept** for potential future applications

# Pneumococcal AMC - how does it work?

## AMC funding sources



“By concluding long-term supply agreements, our Advance Market Commitment has reduced market uncertainty, encouraging manufacturers to develop appropriate products with adequate production capacity and to supply at drastically lower prices.”

Dr Seth Berkley, GAVI Alliance CEO


Price transparency is critical for a country to make an informed decision

“It’s a great example of how innovation and technology together can produce life-saving advances and make them available to people who need them around the world”

Bill Gates, Co-chair of the Bill & Melinda Gates Foundation

\*Co-financing levels will be in line with the applicable GAVI co-financing policy.

# Clear policy pathway is integral – the immunization example



# Demand-side Innovation Policies – take aways

- Countries need to understand value proposition innovations offer
  - Data/evidence base: what evidence is there to substantiate the value proposition?
  - Benefits: what are the benefits the market will derive from the product or service?
  - Alternatives: what alternative options does the market have to the product or service?
- Other important considerations
  - Sufficient visibility into future
  - Transparent decision making

# Thank you



GAVI/2011/Ed Harris